Sales of PCR testing reagents and antibody test kits
First written in FY2020-Q3. 6 of 17 entries say "Advanced", first in FY2020. Latest entry: FY2025-H1.
ImageONE moved to the "Worse" side of this theme in 2024, 2 years after the typical company in this theme (2022).
The whole theme swung hardest in 2022: 5 of 8 companies on the "Worse" side.
0 other companies' latest entry also says "Worsened".
- FY2025-H1WorsenedAnnual report
「In the Medical Supplies segment, as COVID-19 symptoms continued to ease, demand for antigen test kits declined from the previous fiscal year, resulting in sales and profit substantially below the same period of the previous year.」
Due to declining demand for antigen test kits, sales and profit from testing-related products fell substantially below the same period of the previous year. - FY2024WorsenedAnnual report
「In the Medical Supplies segment, demand for antigen test kits declined from the previous fiscal year as COVID-19 symptoms continued to ease, resulting in sales and profit substantially below the previous fiscal year.」
Demand for infection-related products continued to contract, and sales and profit, mainly from antigen test kits, fell substantially below the previous fiscal year. - FY2024-Q2WorsenedAnnual report
「As COVID-19 symptoms continued to ease and infection-control measures were relaxed, demand for antigen test kits, PCR detection reagents and other products declined, and order activity for antigen test kits and other products contracted.」
Demand for testing-related products and order activity continued to contract, and sales and profit in the Healthcare Solutions business fell substantially below the same period of the previous year. - FY2024-Q1WorsenedAnnual report
「As COVID-19 improved and infection-control measures were eased, demand for antigen test kits, PCR detection reagents and other products continued to contract, resulting in sales and profit substantially below the same period of the previous year.」
Demand for testing-related products continued to contract, and sales and profit in the Medical Supplies segment fell substantially below the same period of the previous year. - FY2023WorsenedAnnual report
「Demand for antigen test kits, PCR detection reagents and other products contracted as COVID-19 improved and infection-control measures were eased, resulting in performance substantially below the initial budget.」
The contraction in demand for antigen test kits, PCR detection reagents and other products was reflected in full-year performance, and the Medical Supplies segment fell substantially below budget. - FY2023-Q3WorsenedAnnual report
「Demand for antigen test kits, PCR detection reagents and other products contracted as COVID-19 improved and infection-control measures were eased. Although orders fell short of the initial forecast, a certain level of sales and profit was secured.」
Demand for antigen test kits, PCR detection reagents and other products contracted as the infection situation improved and infection-control measures were eased, causing orders to fall short of the initial forecast. The company reports that a certain level of sales and profit was secured. - FY2023-Q2RestatedAnnual report
「However, as COVID-19 gradually improved and restrictions on infection-control measures were eased, orders for antigen test kits, PCR detection reagents and other products fell short of the orders anticipated by the Group, although a certain level of sales and profit was secured.」
Although antigen test kits, PCR detection reagents and other products generated a certain level of sales and profit, orders have continued to fall short of expectations. - FY2023-Q1Profit secured despite orders falling short of expectationsAnnual report
「Orders for antigen test kits, medical gloves, PCR detection reagents and other products fell short of the orders anticipated by the Group amid the continuing spread of the eighth wave of COVID-19 after the end of the seventh wave, but the Group secured a certain level of sales and profit.」
Orders for antigen test kits, medical gloves, PCR detection reagents and other products fell short of expectations, but a certain level of sales and profit was secured. - FY2022AdvancedAnnual report
「In the Medical Supplies business, sales recognized from orders for medical gloves, PCR detection reagents, antigen test kits and other products are substantially above budget, making a significant contribution to performance.」
The company handled medical gloves in addition to PCR detection reagents, antigen test kits and other products, and sales generated by orders substantially exceeded budget, contributing to performance. - FY2022-Q3AdvancedAnnual report
「Regarding conditions in this segment, in the Medical Supplies business, sales recognized from orders for medical gloves, PCR detection reagents, antigen test kits and other products are substantially above budget, making a significant contribution to performance.」
The company reports that sales generated by orders for medical gloves, PCR detection reagents, antigen test kits and other products substantially exceeded budget and made a significant contribution to performance. - FY2022-Q2AdvancedAnnual report
「In the Medical Supplies business, sales recognized from orders for medical gloves, PCR detection reagents, antigen test kits and other products are substantially above budget, making a significant contribution to performance.」
The company reports that sales generated by orders for PCR detection reagents, antigen test kits and other products substantially exceeded budget and made a significant contribution to performance. - FY2022-Q1RestatedAnnual report
「Orders for COVID-19-related products, including PCR testing reagents and antigen test kits, have continued to exceed the division's budget for the current fiscal year and are expected to make a significant contribution to the recovery of business performance during the current fiscal year.」
The company continues to report that orders for PCR detection reagents, antigen test kits and other products are exceeding the division's budget, and expects them to make a significant contribution to the recovery of current-period performance. - FY2021-Q3AdvancedAnnual report
「Orders for COVID-19-related products, including PCR detection reagents, remain active. They are significantly above the initial plan for the current fiscal year and are expected to contribute to society as business performance recovers during the current fiscal year.」
Orders for COVID-19-related products, including PCR detection reagents, are active and significantly above the initial plan for the current fiscal year. - FY2021-Q2RestatedAnnual report
「Orders for COVID-19-related products, including COVID-19 testing operation systems and PCR detection reagents, remain active and are expected to contribute to the recovery of business performance during the current fiscal year as well as to society.」
The Company stated that orders for COVID-19-related products, including PCR detection reagents, remained active. - FY2021-Q1AdvancedAnnual report
「Orders for COVID-19-related products, including COVID-19 testing operation systems and PCR detection reagents, are currently exceeding the division's budget for the current fiscal year and are expected to contribute to a recovery in business performance during the current fiscal year.」
Orders for COVID-19 testing operation systems, PCR detection reagents, and other products are exceeding the division's budget for the current fiscal year. - FY2020AdvancedAnnual report
「The Company also began handling COVID-19-related products, including PCR testing reagents, PCR testing equipment, antigen test kits, and antibody test kits, and these products are expected to contribute to a recovery in business performance next fiscal year.」
The Company began handling PCR testing reagents and equipment, antigen test kits, antibody test kits, and other products as part of its COVID-19 response. - FY2020-Q3First statedAnnual report
「As part of its response to COVID-19, the Company will also actively pursue sales of PCR testing reagents and antibody test kits.」
The Company indicated a policy of actively pursuing sales of PCR testing reagents and antibody test kits as a new COVID-19 response initiative.